FENNEC PHARMACEUTICALS INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $2.0M | $201.0K | $-638.0K | $-3.2M | $-1.2M | $-5.7M | $-5.6M | $12.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $990.0K | — | — | $798.0K | — | — | $1.2M |
| Net Cash from Operating Activities | $50.0K | $2.4M | $1.5M | $-3.7M | $-4.3M | $-2.2M | $-8.4M | $39.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $1.0M | — | — | $359.0K | — | — | $-1.1M |
| Net Change in Cash | — | $3.4M | — | — | $-4.0M | — | — | $37.9M |
| Free Cash Flow | — | — | — | — | — | — | — | — |